Marked supratherapeutic anticoagulation following S-1 therapy despite low-dose warfarin in a postgastrectomy Japanese patient: a case report highlighting sequential pharmacokinetic and pharmacodynamic risk factors
This case report describes a postgastrectomy Japanese patient on low-dose warfarin who developed life-threatening supratherapeutic anticoagulation during S-1 therapy, illustrating how the convergence of a low warfarin dose requirement, transient renal impairment, and persistent gastrointestinal symptoms can sequentially amplify anticoagulant effects despite dose reductions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Medicine often relies on a delicate balance, where a drug that saves a life can also pose a serious threat if the body processes it differently than expected. This is especially true for blood thinners, medications designed to prevent dangerous clots from forming inside the heart or blood vessels. One such drug, warfarin, has been a mainstay of treatment for decades. It works by interfering with the body's ability to use vitamin K, a nutrient essential for making blood clot. Because every person's body handles this drug differently, doctors must carefully adjust the dose for each patient, aiming for a level that is high enough to prevent clots but low enough to avoid bleeding. When patients take other medicines that change how their body processes warfarin, or when their diet or health status shifts, this balance can tip dangerously. The question of how to manage these changes, particularly in patients taking multiple medications for complex conditions, remains a critical challenge for modern healthcare.
This story begins with a sixty-nine-year-old man in Japan who had been living with a history of heart trouble and a blood clot in his heart. For five years, he had taken a small daily dose of warfarin, just one milligram, to keep his blood from clotting too easily. He also took another heart medication called amiodarone, which is known to make the body more sensitive to warfarin, requiring even smaller doses. After he underwent surgery to remove part of his stomach due to advanced cancer, doctors began a new treatment plan to fight the remaining cancer cells. This plan included a chemotherapy drug called S-1, which is a common treatment for stomach cancer in Japan. The doctors had already adjusted the chemotherapy dose downward because the patient's kidneys were not working at full capacity, a condition that can affect how drugs are cleared from the body.
The situation seemed manageable at first. The patient took the chemotherapy and his low dose of warfarin as prescribed. However, about two weeks into the treatment, his health began to change in ways that set off a chain reaction. He developed a fever, severe diarrhea, and a loss of appetite. These symptoms persisted even after he finished the scheduled course of chemotherapy. As his body struggled with the illness, his kidneys became slightly less efficient at filtering waste, and his weight dropped significantly. The diarrhea and lack of eating meant his body was absorbing far less vitamin K from his food than usual. Since warfarin works by blocking the effects of vitamin K, having less of it in the system made the small dose of warfarin the patient was taking suddenly much more powerful.
The result was a dangerous surge in the blood's inability to clot. About three weeks after starting the chemotherapy, the patient began to bleed from his nose and experienced internal bleeding that showed up as black, tarry stools. When doctors tested his blood, they found a measure of clotting time called the PT-INR had soared above eight. For context, a normal range for someone on this medication is usually between two and three. A reading above eight indicates a severe risk of uncontrolled bleeding. The patient's hemoglobin level, which measures the oxygen-carrying capacity of the blood, had fallen dangerously low. Doctors immediately stopped the warfarin and gave him a form of vitamin K to help his blood clot again, along with blood transfusions to replace what he had lost.
What makes this case particularly important is that the patient did not have a genetic makeup that would normally explain such a dramatic reaction. Scientists tested his DNA and found he did not carry the specific gene variations that typically make people extremely sensitive to warfarin. He was not taking a high dose of the blood thinner, and the chemotherapy dose had already been reduced because of his kidney issues. Yet, the combination of a low baseline dose, a temporary decline in kidney function during treatment, and persistent digestive symptoms created a perfect storm. The reduced kidney function likely caused the chemotherapy drug to stay in his body longer, while the ongoing diarrhea and poor appetite starved his system of the vitamin K needed to counteract the blood thinner.
The researchers concluded that this event was not caused by a single factor, but by a sequence of clinical changes that converged to amplify the drug's effect. Even though the patient was on a very low dose of warfarin and a reduced dose of chemotherapy, the dynamic nature of his health status—specifically the lingering digestive problems and fluctuating kidney function—pushed him into a dangerous zone. The study highlights that doctors cannot rely solely on a patient's starting dose or genetic test results to predict safety. Instead, they must remain vigilant for changes in a patient's condition, such as weight loss, diarrhea, or kidney function, especially after a patient has finished a course of treatment. The danger did not disappear when the chemotherapy stopped; the effects lingered, and the patient's blood remained dangerously thin for days afterward. This case serves as a reminder that in the complex interplay of medicines and the human body, the most significant risks can arise from the accumulation of small, changing factors rather than a single, obvious cause.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.